US Stem Cell (US Stem Cell) EBIT per Share : $-0.01 (TTM As of Dec. 2022)

View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell EBIT per Share?

US Stem Cell's EBIT per Share for the three months ended in Dec. 2022 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for US Stem Cell's EBIT per Share or its related term are showing as below:

USRM's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

US Stem Cell's EBIT for the three months ended in Dec. 2022 was $-0.38 Mil.

US Stem Cell EBIT per Share Historical Data

The historical data trend for US Stem Cell's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell EBIT per Share Chart

US Stem Cell Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-0.01

US Stem Cell Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

US Stem Cell EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

US Stem Cell's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.168	/	591.558
=	-0.00

US Stem Cell's EBIT per Share for the quarter that ended in Dec. 2022 is calculated as

	EBIT per Share		(Q: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.375	/	634.850
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

US Stem Cell (OTCPK:USRM) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

US Stem Cell EBIT per Share Related Terms

Thank you for viewing the detailed overview of US Stem Cell's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

US Stem Cell (US Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323

Website

http://www.us-stemcell.com

US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

Executives

Murphy William P Jr	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson	director	14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman	director	5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart	director	19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson	director	1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella	officer: Chief Science Officer	1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee	director	54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth	director	1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich	officer: Vice President,Sales&Marketing	482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson	director	11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt	director, 10 percent owner, officer: Executive Chairman & CTO	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott	officer: VP of Public Relations	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325